Hepatitis C Virus NS5A Inhibitor class drugs
2 results
Mavyret (glecaprevir and pibrentasvir)
(Glecaprevir and Pibrentasvir)AbbVie Inc.
Usage: MAVYRET is indicated for treating chronic hepatitis C virus (HCV) genotypes 1-6 in patients aged 3 and older, including those with or without cirrhosis. It is also for patients with HCV genotype 1 who have previously received treatment with an NS5A inhibitor or an NS3/4A protease inhibitor.
Sofosbuvir and velpatasvir (velpatasvir and sofosbuvir)
(Velpatasvir and Sofosbuvir)Asegua Therapeutics LLC
Usage: Sofosbuvir and velpatasvir is indicated for treating chronic hepatitis C virus (HCV) genotype 1-6 infection in adults and pediatric patients aged 3 years and older, including those without cirrhosis, with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin.